bioAffinity Technologies, Inc. (BIAF) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] bioAffinity Technologies Inc (BIAF) 3-Minute Overview ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Simply put, bioAffinity Technologies is a tiny, highly speculative biotech/diagnostics company trying to build value around a noninvasive lung cancer test, but right now the story is still much stronger than the financials. > **📍 Basic Profile** > > Market Cap **$12.33 million** · Biotechnology · NASDAQ NMS - GLOBAL MARKET · Price **$2.74** > **⚡ 3 Things You Should Know** > > 1. 💰 Commercial traction is still fragile: the company is getting attention for CyPath Lung and recent clinical case-study headlines, but its overall business is still deeply unprofitable, with a **-217.5% net margin**. In other words, revenue exists, but it is nowhere near enough to cover the cost base. > > 2. ⚠️ This is trading like a momentum micro-cap, not a stable healthcare stock: the share price jumped **43% in a day**, beta is high at **1.78**, and recent news flow is heavily tied to trading activity and promotional-style coverage. That means short-term price moves may say more about sentiment than fundamentals. > > 3. 📉 The market is skeptical despite the product narrative: analyst sentiment is weak overall, with **0 buys, 3 holds, 1 sell, and 2 strong sells**, and recent earnings misses were severe. Basically, investors who buy here are betting the lung-diagnostics platform scales before dilution or operating losses become the bigger story. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Weak👎 | Net margin -217.5%, far below healthy industry levels | > | Growth Rate | [Data unavailable] | No reliable structured revenue growth series provided | > | Financial Health | Moderate💛 | Debt ratio 39.65%, current ratio 3.65 but cash generation is negative | > | Valuation | Fair | PS 1.27x, but PE unavailable due to losses | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** The company develops and sells noninvasive lung-disease diagnostics, aiming to make money by commercializing tests like **CyPath Lung** to healthcare providers and clinical channels. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | CyPath Lung / diagnostic platform | [Data unavailable] | ↑ | Recent news suggests growing commercial attention and clinical visibility | | Other operations / legacy or supporting revenue | [Data unavailable] | [Data unavailable] | The dataset does not provide segment detail | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 27.86% | Below Average | The product has some gross profit, but not enough to support the operating structure yet | | Net Margin | -217.5% | Below Average | The business is losing more than $2 for every $1 of sales, which is extremely weak | | ROE | -247.5% | Average | Equity returns are deeply negative, a sign that shareholder capital is not producing profits yet | --- #### 📈 How's the Growth? **Growth Assessment:** Slowing | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | Losses remain heavy | **Growth Quality:** > What's interesting is that the growth narrative seems to be coming from **product adoption headlines and case studies**, not from a clean set of strong reported financial growth numbers in this dataset. Recent commentary even mentions investors weighing **2025 revenue declines against surging CyPath Lung sales**, which suggests growth may be real in one product line but not yet broad enough to lift the whole company. --- #### 💰 Financial Health Check **One Sentence:** This looks like a startup with manageable balance-sheet debt, but it is still burning cash and depends on continued access to capital or a meaningful revenue ramp. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 39.65% | <60% safe | ✅Safe | | Current Ratio | 3.65 | >1.5 healthy | ✅Safe | | Cash Flow | [Data unavailable] | >0 | ⚠️Volatile | **Worth noting:** - **Cash flow per share TTM is -0.946**, which points to ongoing cash burn. - **Quick ratio is 0.78**, which is less comfortable than the current ratio and suggests liquidity may depend partly on less-liquid current assets. - **Long-term debt is very low**, so the main issue is not leverage; it is operating losses. --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $0.693 - 52-Week High: $46.53 - Current: $2.74, **Near the low** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(4.5% position) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | [Data unavailable] | [Data unavailable] | [Data unavailable] | | vs Peers | PS 1.27x / PB 5.45x | Industry avg [Data unavailable] | Hard to judge cleanly because loss-making biotech peers often distort comparisons | **What the Current Valuation is Betting On:** > Basically, the stock price is not valuing BIAF like a mature diagnostics company. It is valuing it like an option: the market is saying the company might unlock meaningful value if **CyPath Lung** gains real adoption, but until that happens, investors are heavily discounting the business because of execution risk, weak earnings, and likely funding needs. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-03-16 | Stock cooled off after a strong Friday rally as investors weighed 2025 revenue declines against CyPath Lung sales | Neutral — shows the tug-of-war between improving product traction and weak overall financial performance | | 2026-03-16 | Company highlighted a new clinical case study supporting CyPath Lung for suspicious lung findings | Positive — useful for awareness and credibility, though still not the same as broad reimbursement or large-scale adoption | | 2026-03-16 | Multiple market reports flagged unusual volume, active trading, and gap movement | Neutral/Negative — good for visibility, but it reinforces that the stock is currently driven by trading flow as much as fundamentals | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 27.86% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | -217.5% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | -247.5% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Profit Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | | EPS Growth | [Data unavailable] | [Data unavailable] | [Data unavailable] | [Data unavailable] | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2025-09-30 | -$2.75 | -$4.74 | -72.1% Miss 😟 | | 2025-06-30 | -$3.06 | -$5.10 | -66.7% Miss 😟 | | 2025-03-31 | -$4.90 | -$4.80 | +2.0% Beat 😀 | | 2024-12-31 | -$4.28 | -$6.30 | -47.1% Miss 😟 | **Earnings Trend Interpretation:** Recent earnings quality looks weak. One small beat is outweighed by **three very large misses**, which usually tells you management either has poor cost control, weak revenue visibility, or both. In other words, the market has good reason to stay cautious until results become more predictable. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 0 firms | 0% | | Hold | 3 firms | 50% | | Sell | 1 firm | 16.7% | | Strong Sell | 2 firms | 33.3% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median [Data unavailable]) **vs Current Price:** [Data unavailable] **Insider Activity:** Net [Data unavailable] in past 3 months > No insider transaction data was provided. For a company this small, insider buying would usually be an encouraging sign, while insider selling during cash-burn phases can raise extra questions. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Funding Risk:** The company is heavily loss-making and generating negative cash flow → If commercialization takes longer than expected, it could lead to dilution or additional capital raises. 2. **Execution Risk:** BIAF’s value hinges heavily on CyPath Lung gaining real clinical adoption → If physicians, payers, or health systems do not adopt the test at scale, the investment case weakens quickly. 3. **Volatility Risk:** This is a very small-cap, high-beta stock with unusual-volume trading behavior → If sentiment turns, the share price could swing sharply even without major business changes. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** bioAffinity Technologies is a micro-cap biotech/diagnostics company built around the promise of noninvasive lung cancer testing. > > **Key strength:** The interesting part is that CyPath Lung appears to be gaining clinical visibility, and the company’s debt load is not the main problem. > > **Key risk:** The bigger issue is that losses are still enormous, earnings misses have been ugly, and the stock trades more like a speculative event-driven name than a proven healthcare business. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis